Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3% – What’s Next?

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) were up 6.3% during trading on Tuesday . The company traded as high as $11.57 and last traded at $11.4450. Approximately 448,626 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 850,813 shares. The stock had previously closed at $10.77.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on IMMX shares. Wall Street Zen lowered shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday. Citizens Jmp initiated coverage on shares of Immix Biopharma in a report on Monday, March 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Mizuho initiated coverage on shares of Immix Biopharma in a report on Monday, February 9th. They issued an “outperform” rating and a $14.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma has a consensus rating of “Hold” and an average target price of $15.00.

Immix Biopharma Stock Up 6.6%

The firm has a market capitalization of $608.03 million, a price-to-earnings ratio of -14.91 and a beta of 0.25. The business’s fifty day moving average is $6.99 and its 200 day moving average is $4.84.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Persistent Asset Partners Ltd acquired a new stake in Immix Biopharma in the 4th quarter valued at approximately $166,000. United Capital Financial Advisors LLC bought a new position in shares of Immix Biopharma during the 3rd quarter worth approximately $148,000. Imprint Wealth LLC acquired a new stake in shares of Immix Biopharma in the third quarter valued at approximately $141,000. Quadrature Capital Ltd bought a new stake in shares of Immix Biopharma in the fourth quarter worth $116,000. Finally, Squarepoint Ops LLC acquired a new position in Immix Biopharma during the fourth quarter worth $112,000. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.